Allen Bond

Global Heparin Market: Trend Analysis and Forecast to 2022

Press Release   •   Feb 22, 2017 12:42 IST

Heparin is a Sulphur Containing Polysaccharide, used as an anticoagulant in the treatment of thrombosis. Heparin is an injectable blood thinner that primarily prevents the formation of blood clots and is produced in the body by basophils and mast cells. Moreover, it is used to prevent and treat deep vein thrombosis and pulmonary embolism, myocardial infarction and unstable angina. Heparin is usually stored within the secretory granules of mast cells and released only into the vasculature at sites of tissue injury. The global heparin market witnessed lucrative growth over the past few years owing to rising heart diseases and rapid lifestyle changes around the world. The global heparin market is projected to grow CAGR between 6.0% – 6.3% over the forecast period of 2016-2022 and expected to surpass USD 12 billion by 2022.

Globally, the heparin market is growing steadily due to increasing incidences of coagulation disorders, substantial growth in the number of the people suffering from diseases like Venous Thromboembolism (VTE), deep vein thrombosis and heart diseases. In addition, the considerable rise in the prevalence of the obesity is also expected to support the global growth of this market. However, stringent regulatory framework across different regions and side effects of the porcine heparin are likely to limit the global growth of heparin market. A heparin market is expected to experience adoption of synthetic heparin by leading players in the industry. With adoption of synthetic heparin, the global market is anticipated to augment the opportunities for the leading market player in the industry over the forecast period. Furthermore, Technological advancement and rising demand for heparin also expected to escalate growth in this market over the forecast period.

Segments Covered:

The report segments the global heparin market by type of product, route of administration, application, end users and regions. Product segment includes unfractionated heparin, low molecular weight heparin (LMWH) and ultra-molecular weight heparin (UMWH). Route of administration segment comprises IV injection, subcutaneous injection. The application segment includes Clinical trials, medical devices and venous Thromboembolism with the end user segment comprises hospital, blood and steam banks and others.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. Asia pacific, North America and ROW are considered to be the prominent markets for heparin, whereas Asia pacific is expected to be the largest geographic segment growing at a CAGR from of XX% over the forecaste period. On the other hand, North America dominated the global market and registered as the highest revenue generating region in 2014. The growth heparin market in North America region is attributed to the sophisticated healthcare infrastructure; increasing number of medical tourists and large number of surgical procedures conducted in the country.

Companies Profiled:

The companies covered in the report include

  • Sanofi SA
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Leo Pharma
  • Dr. Reddy’s Laboratories
  • Fresenius SE & Co. KG
  • Teva Pharmaceutical Industries Ltd.
  • Baxter International
  • Aspen Holdings

nfinium Global Research and Consulting Solutions is started with a single motto of being business partner of first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you